nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CYP2C8—Sorafenib—thyroid cancer	0.0356	0.177	CbGbCtD
Bortezomib—CYP2C19—Sorafenib—thyroid cancer	0.0298	0.148	CbGbCtD
Bortezomib—CYP1A2—Sorafenib—thyroid cancer	0.0275	0.137	CbGbCtD
Bortezomib—CYP2C9—Sorafenib—thyroid cancer	0.0248	0.123	CbGbCtD
Bortezomib—CYP3A4—Vandetanib—thyroid cancer	0.0239	0.119	CbGbCtD
Bortezomib—CYP2D6—Sorafenib—thyroid cancer	0.0227	0.113	CbGbCtD
Bortezomib—CYP3A4—Sorafenib—thyroid cancer	0.0144	0.0717	CbGbCtD
Bortezomib—CYP2D6—Doxorubicin—thyroid cancer	0.0138	0.0684	CbGbCtD
Bortezomib—CYP3A4—Doxorubicin—thyroid cancer	0.00875	0.0435	CbGbCtD
Bortezomib—PSMD2—Afatinib—Vandetanib—thyroid cancer	0.0073	1	CbGdCrCtD
Bortezomib—PSMD1—saliva-secreting gland—thyroid cancer	0.00672	0.0479	CbGeAlD
Bortezomib—CTSG—trachea—thyroid cancer	0.00643	0.0458	CbGeAlD
Bortezomib—PSMD2—saliva-secreting gland—thyroid cancer	0.00595	0.0424	CbGeAlD
Bortezomib—PSMB8—saliva-secreting gland—thyroid cancer	0.00591	0.0422	CbGeAlD
Bortezomib—PSMB5—saliva-secreting gland—thyroid cancer	0.00522	0.0372	CbGeAlD
Bortezomib—PSMD1—trachea—thyroid cancer	0.00518	0.0369	CbGeAlD
Bortezomib—PSMA1—thyroid gland—thyroid cancer	0.00488	0.0348	CbGeAlD
Bortezomib—PSMD2—trachea—thyroid cancer	0.00459	0.0327	CbGeAlD
Bortezomib—PSMB1—saliva-secreting gland—thyroid cancer	0.00457	0.0325	CbGeAlD
Bortezomib—PSMB8—trachea—thyroid cancer	0.00456	0.0325	CbGeAlD
Bortezomib—PSMB2—saliva-secreting gland—thyroid cancer	0.00445	0.0318	CbGeAlD
Bortezomib—PSMA1—head—thyroid cancer	0.00433	0.0309	CbGeAlD
Bortezomib—PSMD1—thyroid gland—thyroid cancer	0.0041	0.0292	CbGeAlD
Bortezomib—PSMB5—trachea—thyroid cancer	0.00403	0.0287	CbGeAlD
Bortezomib—SLC31A1—saliva-secreting gland—thyroid cancer	0.00386	0.0275	CbGeAlD
Bortezomib—PSMD2—thyroid gland—thyroid cancer	0.00363	0.0259	CbGeAlD
Bortezomib—PSMB8—thyroid gland—thyroid cancer	0.00361	0.0257	CbGeAlD
Bortezomib—PSMB1—trachea—thyroid cancer	0.00352	0.0251	CbGeAlD
Bortezomib—PSMB2—trachea—thyroid cancer	0.00344	0.0245	CbGeAlD
Bortezomib—PSMD2—head—thyroid cancer	0.00322	0.023	CbGeAlD
Bortezomib—PSMB5—thyroid gland—thyroid cancer	0.00319	0.0227	CbGeAlD
Bortezomib—CTSG—lymph node—thyroid cancer	0.00316	0.0225	CbGeAlD
Bortezomib—PSMA1—lymph node—thyroid cancer	0.00303	0.0216	CbGeAlD
Bortezomib—SLC31A1—trachea—thyroid cancer	0.00298	0.0212	CbGeAlD
Bortezomib—PSMB1—thyroid gland—thyroid cancer	0.00279	0.0199	CbGeAlD
Bortezomib—PSMB2—thyroid gland—thyroid cancer	0.00272	0.0194	CbGeAlD
Bortezomib—PSMD1—lymph node—thyroid cancer	0.00255	0.0182	CbGeAlD
Bortezomib—PSMB1—head—thyroid cancer	0.00247	0.0176	CbGeAlD
Bortezomib—PSMB2—head—thyroid cancer	0.00241	0.0172	CbGeAlD
Bortezomib—SLC31A1—thyroid gland—thyroid cancer	0.00235	0.0168	CbGeAlD
Bortezomib—PSMD2—lymph node—thyroid cancer	0.00226	0.0161	CbGeAlD
Bortezomib—PSMB8—lymph node—thyroid cancer	0.00224	0.016	CbGeAlD
Bortezomib—SLC31A1—head—thyroid cancer	0.00209	0.0149	CbGeAlD
Bortezomib—PSMB5—lymph node—thyroid cancer	0.00198	0.0141	CbGeAlD
Bortezomib—PSMB1—lymph node—thyroid cancer	0.00173	0.0123	CbGeAlD
Bortezomib—PSMB2—lymph node—thyroid cancer	0.00169	0.012	CbGeAlD
Bortezomib—SLC31A1—lymph node—thyroid cancer	0.00146	0.0104	CbGeAlD
Bortezomib—Nateglinide—PPARG—thyroid cancer	0.00135	1	CrCbGaD
Bortezomib—CYP1A1—trachea—thyroid cancer	0.00101	0.00721	CbGeAlD
Bortezomib—PTGS1—trachea—thyroid cancer	0.000888	0.00633	CbGeAlD
Bortezomib—CYP1A2—thyroid gland—thyroid cancer	0.000811	0.00578	CbGeAlD
Bortezomib—CYP1A1—thyroid gland—thyroid cancer	0.0008	0.0057	CbGeAlD
Bortezomib—CYP1A1—head—thyroid cancer	0.000709	0.00506	CbGeAlD
Bortezomib—PTGS1—thyroid gland—thyroid cancer	0.000702	0.00501	CbGeAlD
Bortezomib—PTGS1—head—thyroid cancer	0.000623	0.00444	CbGeAlD
Bortezomib—CYP2D6—head—thyroid cancer	0.000512	0.00365	CbGeAlD
Bortezomib—CYP1A1—lymph node—thyroid cancer	0.000497	0.00354	CbGeAlD
Bortezomib—PTGS1—lymph node—thyroid cancer	0.000436	0.00311	CbGeAlD
Bortezomib—Dry skin—Epirubicin—thyroid cancer	0.000167	0.00041	CcSEcCtD
Bortezomib—Orthostatic hypotension—Epirubicin—thyroid cancer	0.000166	0.000408	CcSEcCtD
Bortezomib—Abdominal pain upper—Epirubicin—thyroid cancer	0.000166	0.000408	CcSEcCtD
Bortezomib—Migraine—Doxorubicin—thyroid cancer	0.000166	0.000407	CcSEcCtD
Bortezomib—Hypokalaemia—Epirubicin—thyroid cancer	0.000166	0.000407	CcSEcCtD
Bortezomib—Diarrhoea—Sorafenib—thyroid cancer	0.000166	0.000407	CcSEcCtD
Bortezomib—Breast disorder—Epirubicin—thyroid cancer	0.000165	0.000404	CcSEcCtD
Bortezomib—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000164	0.000403	CcSEcCtD
Bortezomib—Nasopharyngitis—Epirubicin—thyroid cancer	0.000163	0.0004	CcSEcCtD
Bortezomib—Face oedema—Doxorubicin—thyroid cancer	0.000163	0.0004	CcSEcCtD
Bortezomib—Gastritis—Epirubicin—thyroid cancer	0.000161	0.000396	CcSEcCtD
Bortezomib—Muscular weakness—Epirubicin—thyroid cancer	0.000161	0.000394	CcSEcCtD
Bortezomib—Cardiac arrest—Doxorubicin—thyroid cancer	0.00016	0.000393	CcSEcCtD
Bortezomib—Dizziness—Sorafenib—thyroid cancer	0.00016	0.000393	CcSEcCtD
Bortezomib—Abdominal distension—Epirubicin—thyroid cancer	0.000159	0.000389	CcSEcCtD
Bortezomib—Ataxia—Doxorubicin—thyroid cancer	0.000159	0.000389	CcSEcCtD
Bortezomib—Influenza—Epirubicin—thyroid cancer	0.000157	0.000387	CcSEcCtD
Bortezomib—Dysphagia—Epirubicin—thyroid cancer	0.000157	0.000387	CcSEcCtD
Bortezomib—Dehydration—Doxorubicin—thyroid cancer	0.000157	0.000385	CcSEcCtD
Bortezomib—Dry skin—Doxorubicin—thyroid cancer	0.000155	0.000379	CcSEcCtD
Bortezomib—Pancreatitis—Epirubicin—thyroid cancer	0.000154	0.000379	CcSEcCtD
Bortezomib—Vomiting—Sorafenib—thyroid cancer	0.000154	0.000378	CcSEcCtD
Bortezomib—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000154	0.000378	CcSEcCtD
Bortezomib—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000154	0.000378	CcSEcCtD
Bortezomib—Hypokalaemia—Doxorubicin—thyroid cancer	0.000153	0.000377	CcSEcCtD
Bortezomib—Angina pectoris—Epirubicin—thyroid cancer	0.000153	0.000377	CcSEcCtD
Bortezomib—Rash—Sorafenib—thyroid cancer	0.000153	0.000375	CcSEcCtD
Bortezomib—Dermatitis—Sorafenib—thyroid cancer	0.000153	0.000375	CcSEcCtD
Bortezomib—Breast disorder—Doxorubicin—thyroid cancer	0.000152	0.000374	CcSEcCtD
Bortezomib—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000152	0.000373	CcSEcCtD
Bortezomib—Headache—Sorafenib—thyroid cancer	0.000152	0.000373	CcSEcCtD
Bortezomib—Bronchitis—Epirubicin—thyroid cancer	0.000151	0.000372	CcSEcCtD
Bortezomib—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000151	0.00037	CcSEcCtD
Bortezomib—Pancytopenia—Epirubicin—thyroid cancer	0.00015	0.000367	CcSEcCtD
Bortezomib—Gastritis—Doxorubicin—thyroid cancer	0.000149	0.000366	CcSEcCtD
Bortezomib—Muscular weakness—Doxorubicin—thyroid cancer	0.000149	0.000365	CcSEcCtD
Bortezomib—Neutropenia—Epirubicin—thyroid cancer	0.000147	0.000361	CcSEcCtD
Bortezomib—Abdominal distension—Doxorubicin—thyroid cancer	0.000147	0.00036	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000146	0.000359	CcSEcCtD
Bortezomib—Influenza—Doxorubicin—thyroid cancer	0.000146	0.000358	CcSEcCtD
Bortezomib—Dysphagia—Doxorubicin—thyroid cancer	0.000146	0.000358	CcSEcCtD
Bortezomib—Pollakiuria—Epirubicin—thyroid cancer	0.000145	0.000357	CcSEcCtD
Bortezomib—Nausea—Sorafenib—thyroid cancer	0.000144	0.000353	CcSEcCtD
Bortezomib—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000144	0.000353	CcSEcCtD
Bortezomib—Weight increased—Epirubicin—thyroid cancer	0.000143	0.000352	CcSEcCtD
Bortezomib—Pancreatitis—Doxorubicin—thyroid cancer	0.000143	0.000351	CcSEcCtD
Bortezomib—Weight decreased—Epirubicin—thyroid cancer	0.000142	0.00035	CcSEcCtD
Bortezomib—Hyperglycaemia—Epirubicin—thyroid cancer	0.000142	0.000349	CcSEcCtD
Bortezomib—Angina pectoris—Doxorubicin—thyroid cancer	0.000142	0.000348	CcSEcCtD
Bortezomib—Pneumonia—Epirubicin—thyroid cancer	0.000141	0.000347	CcSEcCtD
Bortezomib—Infestation NOS—Epirubicin—thyroid cancer	0.00014	0.000345	CcSEcCtD
Bortezomib—Infestation—Epirubicin—thyroid cancer	0.00014	0.000345	CcSEcCtD
Bortezomib—Bronchitis—Doxorubicin—thyroid cancer	0.00014	0.000344	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000139	0.000342	CcSEcCtD
Bortezomib—Pancytopenia—Doxorubicin—thyroid cancer	0.000138	0.00034	CcSEcCtD
Bortezomib—Renal failure—Epirubicin—thyroid cancer	0.000138	0.000339	CcSEcCtD
Bortezomib—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000138	0.000338	CcSEcCtD
Bortezomib—Stomatitis—Epirubicin—thyroid cancer	0.000137	0.000336	CcSEcCtD
Bortezomib—Conjunctivitis—Epirubicin—thyroid cancer	0.000136	0.000335	CcSEcCtD
Bortezomib—Urinary tract infection—Epirubicin—thyroid cancer	0.000136	0.000335	CcSEcCtD
Bortezomib—Neutropenia—Doxorubicin—thyroid cancer	0.000136	0.000334	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000135	0.000332	CcSEcCtD
Bortezomib—Pollakiuria—Doxorubicin—thyroid cancer	0.000135	0.00033	CcSEcCtD
Bortezomib—Haematuria—Epirubicin—thyroid cancer	0.000134	0.000329	CcSEcCtD
Bortezomib—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000133	0.000326	CcSEcCtD
Bortezomib—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000133	0.000326	CcSEcCtD
Bortezomib—Weight increased—Doxorubicin—thyroid cancer	0.000133	0.000325	CcSEcCtD
Bortezomib—Epistaxis—Epirubicin—thyroid cancer	0.000132	0.000325	CcSEcCtD
Bortezomib—Weight decreased—Doxorubicin—thyroid cancer	0.000132	0.000324	CcSEcCtD
Bortezomib—Sinusitis—Epirubicin—thyroid cancer	0.000132	0.000323	CcSEcCtD
Bortezomib—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000131	0.000323	CcSEcCtD
Bortezomib—Pneumonia—Doxorubicin—thyroid cancer	0.000131	0.000321	CcSEcCtD
Bortezomib—Infestation NOS—Doxorubicin—thyroid cancer	0.00013	0.000319	CcSEcCtD
Bortezomib—Infestation—Doxorubicin—thyroid cancer	0.00013	0.000319	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000129	0.000316	CcSEcCtD
Bortezomib—Bradycardia—Epirubicin—thyroid cancer	0.000128	0.000315	CcSEcCtD
Bortezomib—Renal failure—Doxorubicin—thyroid cancer	0.000128	0.000313	CcSEcCtD
Bortezomib—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000127	0.000313	CcSEcCtD
Bortezomib—Haemoglobin—Epirubicin—thyroid cancer	0.000127	0.000311	CcSEcCtD
Bortezomib—Stomatitis—Doxorubicin—thyroid cancer	0.000127	0.000311	CcSEcCtD
Bortezomib—Conjunctivitis—Doxorubicin—thyroid cancer	0.000126	0.00031	CcSEcCtD
Bortezomib—Urinary tract infection—Doxorubicin—thyroid cancer	0.000126	0.00031	CcSEcCtD
Bortezomib—Haemorrhage—Epirubicin—thyroid cancer	0.000126	0.000309	CcSEcCtD
Bortezomib—Hepatitis—Epirubicin—thyroid cancer	0.000126	0.000309	CcSEcCtD
Bortezomib—Hypoaesthesia—Epirubicin—thyroid cancer	0.000125	0.000308	CcSEcCtD
Bortezomib—Urinary tract disorder—Epirubicin—thyroid cancer	0.000124	0.000306	CcSEcCtD
Bortezomib—Oedema peripheral—Epirubicin—thyroid cancer	0.000124	0.000305	CcSEcCtD
Bortezomib—Haematuria—Doxorubicin—thyroid cancer	0.000124	0.000304	CcSEcCtD
Bortezomib—Connective tissue disorder—Epirubicin—thyroid cancer	0.000124	0.000304	CcSEcCtD
Bortezomib—Urethral disorder—Epirubicin—thyroid cancer	0.000124	0.000303	CcSEcCtD
Bortezomib—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000123	0.000302	CcSEcCtD
Bortezomib—Epistaxis—Doxorubicin—thyroid cancer	0.000123	0.000301	CcSEcCtD
Bortezomib—Sinusitis—Doxorubicin—thyroid cancer	0.000122	0.000299	CcSEcCtD
Bortezomib—Visual impairment—Epirubicin—thyroid cancer	0.000121	0.000298	CcSEcCtD
Bortezomib—Erythema multiforme—Epirubicin—thyroid cancer	0.000119	0.000293	CcSEcCtD
Bortezomib—Bradycardia—Doxorubicin—thyroid cancer	0.000119	0.000291	CcSEcCtD
Bortezomib—Eye disorder—Epirubicin—thyroid cancer	0.000118	0.000289	CcSEcCtD
Bortezomib—Tinnitus—Epirubicin—thyroid cancer	0.000118	0.000288	CcSEcCtD
Bortezomib—Haemoglobin—Doxorubicin—thyroid cancer	0.000117	0.000288	CcSEcCtD
Bortezomib—Flushing—Epirubicin—thyroid cancer	0.000117	0.000287	CcSEcCtD
Bortezomib—Cardiac disorder—Epirubicin—thyroid cancer	0.000117	0.000287	CcSEcCtD
Bortezomib—Hepatitis—Doxorubicin—thyroid cancer	0.000117	0.000286	CcSEcCtD
Bortezomib—Haemorrhage—Doxorubicin—thyroid cancer	0.000117	0.000286	CcSEcCtD
Bortezomib—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000116	0.000285	CcSEcCtD
Bortezomib—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000115	0.000283	CcSEcCtD
Bortezomib—Oedema peripheral—Doxorubicin—thyroid cancer	0.000115	0.000282	CcSEcCtD
Bortezomib—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000115	0.000281	CcSEcCtD
Bortezomib—Angiopathy—Epirubicin—thyroid cancer	0.000114	0.000281	CcSEcCtD
Bortezomib—Urethral disorder—Doxorubicin—thyroid cancer	0.000114	0.000281	CcSEcCtD
Bortezomib—Immune system disorder—Epirubicin—thyroid cancer	0.000114	0.000279	CcSEcCtD
Bortezomib—Mediastinal disorder—Epirubicin—thyroid cancer	0.000114	0.000279	CcSEcCtD
Bortezomib—Chills—Epirubicin—thyroid cancer	0.000113	0.000278	CcSEcCtD
Bortezomib—Arrhythmia—Epirubicin—thyroid cancer	0.000113	0.000276	CcSEcCtD
Bortezomib—Visual impairment—Doxorubicin—thyroid cancer	0.000112	0.000276	CcSEcCtD
Bortezomib—Mental disorder—Epirubicin—thyroid cancer	0.00011	0.000271	CcSEcCtD
Bortezomib—Erythema multiforme—Doxorubicin—thyroid cancer	0.00011	0.000271	CcSEcCtD
Bortezomib—Malnutrition—Epirubicin—thyroid cancer	0.00011	0.000269	CcSEcCtD
Bortezomib—Erythema—Epirubicin—thyroid cancer	0.00011	0.000269	CcSEcCtD
Bortezomib—Eye disorder—Doxorubicin—thyroid cancer	0.000109	0.000268	CcSEcCtD
Bortezomib—Tinnitus—Doxorubicin—thyroid cancer	0.000109	0.000267	CcSEcCtD
Bortezomib—Flushing—Doxorubicin—thyroid cancer	0.000108	0.000266	CcSEcCtD
Bortezomib—Cardiac disorder—Doxorubicin—thyroid cancer	0.000108	0.000266	CcSEcCtD
Bortezomib—Flatulence—Epirubicin—thyroid cancer	0.000108	0.000265	CcSEcCtD
Bortezomib—Dysgeusia—Epirubicin—thyroid cancer	0.000107	0.000264	CcSEcCtD
Bortezomib—Back pain—Epirubicin—thyroid cancer	0.000106	0.000261	CcSEcCtD
Bortezomib—Angiopathy—Doxorubicin—thyroid cancer	0.000106	0.00026	CcSEcCtD
Bortezomib—Muscle spasms—Epirubicin—thyroid cancer	0.000105	0.000259	CcSEcCtD
Bortezomib—Immune system disorder—Doxorubicin—thyroid cancer	0.000105	0.000259	CcSEcCtD
Bortezomib—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000105	0.000258	CcSEcCtD
Bortezomib—Chills—Doxorubicin—thyroid cancer	0.000105	0.000257	CcSEcCtD
Bortezomib—Arrhythmia—Doxorubicin—thyroid cancer	0.000104	0.000256	CcSEcCtD
Bortezomib—Vision blurred—Epirubicin—thyroid cancer	0.000103	0.000254	CcSEcCtD
Bortezomib—Mental disorder—Doxorubicin—thyroid cancer	0.000102	0.000251	CcSEcCtD
Bortezomib—Ill-defined disorder—Epirubicin—thyroid cancer	0.000102	0.00025	CcSEcCtD
Bortezomib—Erythema—Doxorubicin—thyroid cancer	0.000102	0.000249	CcSEcCtD
Bortezomib—Malnutrition—Doxorubicin—thyroid cancer	0.000102	0.000249	CcSEcCtD
Bortezomib—Anaemia—Epirubicin—thyroid cancer	0.000101	0.000249	CcSEcCtD
Bortezomib—Agitation—Epirubicin—thyroid cancer	0.000101	0.000248	CcSEcCtD
Bortezomib—Flatulence—Doxorubicin—thyroid cancer	0.0001	0.000246	CcSEcCtD
Bortezomib—Dysgeusia—Doxorubicin—thyroid cancer	9.94e-05	0.000244	CcSEcCtD
Bortezomib—Malaise—Epirubicin—thyroid cancer	9.89e-05	0.000243	CcSEcCtD
Bortezomib—Vertigo—Epirubicin—thyroid cancer	9.86e-05	0.000242	CcSEcCtD
Bortezomib—Syncope—Epirubicin—thyroid cancer	9.84e-05	0.000242	CcSEcCtD
Bortezomib—Leukopenia—Epirubicin—thyroid cancer	9.82e-05	0.000241	CcSEcCtD
Bortezomib—Back pain—Doxorubicin—thyroid cancer	9.82e-05	0.000241	CcSEcCtD
Bortezomib—Muscle spasms—Doxorubicin—thyroid cancer	9.76e-05	0.00024	CcSEcCtD
Bortezomib—Palpitations—Epirubicin—thyroid cancer	9.7e-05	0.000238	CcSEcCtD
Bortezomib—Loss of consciousness—Epirubicin—thyroid cancer	9.64e-05	0.000237	CcSEcCtD
Bortezomib—Cough—Epirubicin—thyroid cancer	9.57e-05	0.000235	CcSEcCtD
Bortezomib—Vision blurred—Doxorubicin—thyroid cancer	9.57e-05	0.000235	CcSEcCtD
Bortezomib—Convulsion—Epirubicin—thyroid cancer	9.51e-05	0.000233	CcSEcCtD
Bortezomib—Hypertension—Epirubicin—thyroid cancer	9.47e-05	0.000233	CcSEcCtD
Bortezomib—Ill-defined disorder—Doxorubicin—thyroid cancer	9.42e-05	0.000231	CcSEcCtD
Bortezomib—Anaemia—Doxorubicin—thyroid cancer	9.38e-05	0.00023	CcSEcCtD
Bortezomib—Arthralgia—Epirubicin—thyroid cancer	9.34e-05	0.000229	CcSEcCtD
Bortezomib—Myalgia—Epirubicin—thyroid cancer	9.34e-05	0.000229	CcSEcCtD
Bortezomib—Chest pain—Epirubicin—thyroid cancer	9.34e-05	0.000229	CcSEcCtD
Bortezomib—Agitation—Doxorubicin—thyroid cancer	9.33e-05	0.000229	CcSEcCtD
Bortezomib—Anxiety—Epirubicin—thyroid cancer	9.31e-05	0.000229	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	9.28e-05	0.000228	CcSEcCtD
Bortezomib—Discomfort—Epirubicin—thyroid cancer	9.23e-05	0.000227	CcSEcCtD
Bortezomib—Malaise—Doxorubicin—thyroid cancer	9.16e-05	0.000225	CcSEcCtD
Bortezomib—Vertigo—Doxorubicin—thyroid cancer	9.12e-05	0.000224	CcSEcCtD
Bortezomib—Syncope—Doxorubicin—thyroid cancer	9.1e-05	0.000223	CcSEcCtD
Bortezomib—Leukopenia—Doxorubicin—thyroid cancer	9.09e-05	0.000223	CcSEcCtD
Bortezomib—Confusional state—Epirubicin—thyroid cancer	9.03e-05	0.000222	CcSEcCtD
Bortezomib—Palpitations—Doxorubicin—thyroid cancer	8.97e-05	0.00022	CcSEcCtD
Bortezomib—Oedema—Epirubicin—thyroid cancer	8.95e-05	0.00022	CcSEcCtD
Bortezomib—Anaphylactic shock—Epirubicin—thyroid cancer	8.95e-05	0.00022	CcSEcCtD
Bortezomib—Loss of consciousness—Doxorubicin—thyroid cancer	8.92e-05	0.000219	CcSEcCtD
Bortezomib—Infection—Epirubicin—thyroid cancer	8.9e-05	0.000218	CcSEcCtD
Bortezomib—Cough—Doxorubicin—thyroid cancer	8.86e-05	0.000217	CcSEcCtD
Bortezomib—Shock—Epirubicin—thyroid cancer	8.81e-05	0.000216	CcSEcCtD
Bortezomib—Convulsion—Doxorubicin—thyroid cancer	8.8e-05	0.000216	CcSEcCtD
Bortezomib—Nervous system disorder—Epirubicin—thyroid cancer	8.78e-05	0.000216	CcSEcCtD
Bortezomib—Thrombocytopenia—Epirubicin—thyroid cancer	8.77e-05	0.000215	CcSEcCtD
Bortezomib—Hypertension—Doxorubicin—thyroid cancer	8.76e-05	0.000215	CcSEcCtD
Bortezomib—Tachycardia—Epirubicin—thyroid cancer	8.74e-05	0.000215	CcSEcCtD
Bortezomib—Skin disorder—Epirubicin—thyroid cancer	8.7e-05	0.000214	CcSEcCtD
Bortezomib—Hyperhidrosis—Epirubicin—thyroid cancer	8.66e-05	0.000213	CcSEcCtD
Bortezomib—Chest pain—Doxorubicin—thyroid cancer	8.64e-05	0.000212	CcSEcCtD
Bortezomib—Myalgia—Doxorubicin—thyroid cancer	8.64e-05	0.000212	CcSEcCtD
Bortezomib—Arthralgia—Doxorubicin—thyroid cancer	8.64e-05	0.000212	CcSEcCtD
Bortezomib—Anxiety—Doxorubicin—thyroid cancer	8.61e-05	0.000211	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	8.58e-05	0.000211	CcSEcCtD
Bortezomib—Discomfort—Doxorubicin—thyroid cancer	8.54e-05	0.00021	CcSEcCtD
Bortezomib—Anorexia—Epirubicin—thyroid cancer	8.54e-05	0.00021	CcSEcCtD
Bortezomib—Hypotension—Epirubicin—thyroid cancer	8.37e-05	0.000205	CcSEcCtD
Bortezomib—Confusional state—Doxorubicin—thyroid cancer	8.35e-05	0.000205	CcSEcCtD
Bortezomib—Anaphylactic shock—Doxorubicin—thyroid cancer	8.29e-05	0.000203	CcSEcCtD
Bortezomib—Oedema—Doxorubicin—thyroid cancer	8.29e-05	0.000203	CcSEcCtD
Bortezomib—Infection—Doxorubicin—thyroid cancer	8.23e-05	0.000202	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Epirubicin—thyroid cancer	8.16e-05	0.0002	CcSEcCtD
Bortezomib—Shock—Doxorubicin—thyroid cancer	8.15e-05	0.0002	CcSEcCtD
Bortezomib—Nervous system disorder—Doxorubicin—thyroid cancer	8.13e-05	0.000199	CcSEcCtD
Bortezomib—Thrombocytopenia—Doxorubicin—thyroid cancer	8.11e-05	0.000199	CcSEcCtD
Bortezomib—Insomnia—Epirubicin—thyroid cancer	8.1e-05	0.000199	CcSEcCtD
Bortezomib—Tachycardia—Doxorubicin—thyroid cancer	8.09e-05	0.000199	CcSEcCtD
Bortezomib—Skin disorder—Doxorubicin—thyroid cancer	8.05e-05	0.000198	CcSEcCtD
Bortezomib—Paraesthesia—Epirubicin—thyroid cancer	8.04e-05	0.000197	CcSEcCtD
Bortezomib—Hyperhidrosis—Doxorubicin—thyroid cancer	8.01e-05	0.000197	CcSEcCtD
Bortezomib—Dyspnoea—Epirubicin—thyroid cancer	7.98e-05	0.000196	CcSEcCtD
Bortezomib—Anorexia—Doxorubicin—thyroid cancer	7.9e-05	0.000194	CcSEcCtD
Bortezomib—Dyspepsia—Epirubicin—thyroid cancer	7.88e-05	0.000193	CcSEcCtD
Bortezomib—Decreased appetite—Epirubicin—thyroid cancer	7.78e-05	0.000191	CcSEcCtD
Bortezomib—Hypotension—Doxorubicin—thyroid cancer	7.74e-05	0.00019	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Epirubicin—thyroid cancer	7.73e-05	0.00019	CcSEcCtD
Bortezomib—Fatigue—Epirubicin—thyroid cancer	7.72e-05	0.00019	CcSEcCtD
Bortezomib—Constipation—Epirubicin—thyroid cancer	7.66e-05	0.000188	CcSEcCtD
Bortezomib—Pain—Epirubicin—thyroid cancer	7.66e-05	0.000188	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	7.55e-05	0.000185	CcSEcCtD
Bortezomib—Insomnia—Doxorubicin—thyroid cancer	7.49e-05	0.000184	CcSEcCtD
Bortezomib—Paraesthesia—Doxorubicin—thyroid cancer	7.44e-05	0.000183	CcSEcCtD
Bortezomib—Dyspnoea—Doxorubicin—thyroid cancer	7.39e-05	0.000181	CcSEcCtD
Bortezomib—Feeling abnormal—Epirubicin—thyroid cancer	7.38e-05	0.000181	CcSEcCtD
Bortezomib—Gastrointestinal pain—Epirubicin—thyroid cancer	7.32e-05	0.00018	CcSEcCtD
Bortezomib—Dyspepsia—Doxorubicin—thyroid cancer	7.29e-05	0.000179	CcSEcCtD
Bortezomib—Decreased appetite—Doxorubicin—thyroid cancer	7.2e-05	0.000177	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Doxorubicin—thyroid cancer	7.15e-05	0.000176	CcSEcCtD
Bortezomib—Fatigue—Doxorubicin—thyroid cancer	7.14e-05	0.000175	CcSEcCtD
Bortezomib—Urticaria—Epirubicin—thyroid cancer	7.11e-05	0.000175	CcSEcCtD
Bortezomib—Constipation—Doxorubicin—thyroid cancer	7.09e-05	0.000174	CcSEcCtD
Bortezomib—Pain—Doxorubicin—thyroid cancer	7.09e-05	0.000174	CcSEcCtD
Bortezomib—Abdominal pain—Epirubicin—thyroid cancer	7.08e-05	0.000174	CcSEcCtD
Bortezomib—Body temperature increased—Epirubicin—thyroid cancer	7.08e-05	0.000174	CcSEcCtD
Bortezomib—Feeling abnormal—Doxorubicin—thyroid cancer	6.83e-05	0.000168	CcSEcCtD
Bortezomib—Gastrointestinal pain—Doxorubicin—thyroid cancer	6.78e-05	0.000166	CcSEcCtD
Bortezomib—Hypersensitivity—Epirubicin—thyroid cancer	6.6e-05	0.000162	CcSEcCtD
Bortezomib—Urticaria—Doxorubicin—thyroid cancer	6.58e-05	0.000162	CcSEcCtD
Bortezomib—Abdominal pain—Doxorubicin—thyroid cancer	6.55e-05	0.000161	CcSEcCtD
Bortezomib—Body temperature increased—Doxorubicin—thyroid cancer	6.55e-05	0.000161	CcSEcCtD
Bortezomib—Asthenia—Epirubicin—thyroid cancer	6.42e-05	0.000158	CcSEcCtD
Bortezomib—Pruritus—Epirubicin—thyroid cancer	6.34e-05	0.000156	CcSEcCtD
Bortezomib—Diarrhoea—Epirubicin—thyroid cancer	6.13e-05	0.00015	CcSEcCtD
Bortezomib—Hypersensitivity—Doxorubicin—thyroid cancer	6.1e-05	0.00015	CcSEcCtD
Bortezomib—Asthenia—Doxorubicin—thyroid cancer	5.94e-05	0.000146	CcSEcCtD
Bortezomib—Dizziness—Epirubicin—thyroid cancer	5.92e-05	0.000145	CcSEcCtD
Bortezomib—Pruritus—Doxorubicin—thyroid cancer	5.86e-05	0.000144	CcSEcCtD
Bortezomib—Vomiting—Epirubicin—thyroid cancer	5.69e-05	0.00014	CcSEcCtD
Bortezomib—Diarrhoea—Doxorubicin—thyroid cancer	5.67e-05	0.000139	CcSEcCtD
Bortezomib—Rash—Epirubicin—thyroid cancer	5.65e-05	0.000139	CcSEcCtD
Bortezomib—Dermatitis—Epirubicin—thyroid cancer	5.64e-05	0.000138	CcSEcCtD
Bortezomib—Headache—Epirubicin—thyroid cancer	5.61e-05	0.000138	CcSEcCtD
Bortezomib—Dizziness—Doxorubicin—thyroid cancer	5.48e-05	0.000134	CcSEcCtD
Bortezomib—Nausea—Epirubicin—thyroid cancer	5.32e-05	0.000131	CcSEcCtD
Bortezomib—Vomiting—Doxorubicin—thyroid cancer	5.27e-05	0.000129	CcSEcCtD
Bortezomib—Rash—Doxorubicin—thyroid cancer	5.22e-05	0.000128	CcSEcCtD
Bortezomib—Dermatitis—Doxorubicin—thyroid cancer	5.22e-05	0.000128	CcSEcCtD
Bortezomib—Headache—Doxorubicin—thyroid cancer	5.19e-05	0.000127	CcSEcCtD
Bortezomib—Nausea—Doxorubicin—thyroid cancer	4.92e-05	0.000121	CcSEcCtD
Bortezomib—PSMD2—Immune System—NRAS—thyroid cancer	3.1e-05	0.000128	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—PTGS2—thyroid cancer	3.1e-05	0.000128	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HPGD—thyroid cancer	3.09e-05	0.000127	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TERT—thyroid cancer	3.08e-05	0.000127	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TERT—thyroid cancer	3.08e-05	0.000127	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TERT—thyroid cancer	3.08e-05	0.000127	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—PTGS2—thyroid cancer	3.08e-05	0.000127	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TERT—thyroid cancer	3.04e-05	0.000125	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PPARG—thyroid cancer	3e-05	0.000124	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PPARG—thyroid cancer	3e-05	0.000124	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PPARG—thyroid cancer	3e-05	0.000124	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PPARG—thyroid cancer	2.95e-05	0.000122	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CHST14—thyroid cancer	2.95e-05	0.000122	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—SLC5A5—thyroid cancer	2.95e-05	0.000122	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HIF1A—thyroid cancer	2.95e-05	0.000122	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HIF1A—thyroid cancer	2.95e-05	0.000122	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HIF1A—thyroid cancer	2.95e-05	0.000122	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.93e-05	0.000121	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HIF1A—thyroid cancer	2.91e-05	0.00012	CbGpPWpGaD
Bortezomib—PSMA1—Disease—NRAS—thyroid cancer	2.89e-05	0.000119	CbGpPWpGaD
Bortezomib—PSMD1—Disease—NRAS—thyroid cancer	2.88e-05	0.000119	CbGpPWpGaD
Bortezomib—PSMD2—Disease—NRAS—thyroid cancer	2.86e-05	0.000118	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—HRAS—thyroid cancer	2.86e-05	0.000118	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—HRAS—thyroid cancer	2.86e-05	0.000118	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—HRAS—thyroid cancer	2.86e-05	0.000118	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—HRAS—thyroid cancer	2.82e-05	0.000116	CbGpPWpGaD
Bortezomib—PSMB2—Disease—PTGS2—thyroid cancer	2.81e-05	0.000116	CbGpPWpGaD
Bortezomib—PSMB5—Disease—PTGS2—thyroid cancer	2.81e-05	0.000116	CbGpPWpGaD
Bortezomib—PSMB1—Disease—PTGS2—thyroid cancer	2.81e-05	0.000116	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—TPR—thyroid cancer	2.78e-05	0.000115	CbGpPWpGaD
Bortezomib—PSMB8—Disease—PTGS2—thyroid cancer	2.77e-05	0.000114	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.77e-05	0.000114	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PRKAR1A—thyroid cancer	2.73e-05	0.000113	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—PTEN—thyroid cancer	2.71e-05	0.000112	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—PTEN—thyroid cancer	2.7e-05	0.000111	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—KRAS—thyroid cancer	2.69e-05	0.000111	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—PTEN—thyroid cancer	2.69e-05	0.000111	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—KRAS—thyroid cancer	2.68e-05	0.000111	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—KRAS—thyroid cancer	2.67e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—PTEN—thyroid cancer	2.66e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—PTEN—thyroid cancer	2.66e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—PTEN—thyroid cancer	2.66e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—PTEN—thyroid cancer	2.62e-05	0.000108	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—TPR—thyroid cancer	2.55e-05	0.000105	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—AKT1—thyroid cancer	2.53e-05	0.000104	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—AKT1—thyroid cancer	2.53e-05	0.000104	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—AKT1—thyroid cancer	2.53e-05	0.000104	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	2.51e-05	0.000103	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.5e-05	0.000103	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—AKT1—thyroid cancer	2.49e-05	0.000103	CbGpPWpGaD
Bortezomib—PSMA1—Disease—KRAS—thyroid cancer	2.49e-05	0.000103	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—RXRA—thyroid cancer	2.48e-05	0.000102	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.48e-05	0.000102	CbGpPWpGaD
Bortezomib—PSMD1—Disease—KRAS—thyroid cancer	2.48e-05	0.000102	CbGpPWpGaD
Bortezomib—PSMD2—Disease—KRAS—thyroid cancer	2.46e-05	0.000102	CbGpPWpGaD
Bortezomib—PSMB5—Disease—PTEN—thyroid cancer	2.45e-05	0.000101	CbGpPWpGaD
Bortezomib—PSMB2—Disease—PTEN—thyroid cancer	2.45e-05	0.000101	CbGpPWpGaD
Bortezomib—PSMB1—Disease—PTEN—thyroid cancer	2.45e-05	0.000101	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—BRAF—thyroid cancer	2.44e-05	0.000101	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—BRAF—thyroid cancer	2.44e-05	0.000101	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—BRAF—thyroid cancer	2.44e-05	0.000101	CbGpPWpGaD
Bortezomib—PSMB8—Disease—PTEN—thyroid cancer	2.42e-05	9.98e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.41e-05	9.95e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—BRAF—thyroid cancer	2.41e-05	9.92e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HPGD—thyroid cancer	2.38e-05	9.82e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—NRAS—thyroid cancer	2.37e-05	9.78e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—NRAS—thyroid cancer	2.37e-05	9.78e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—NRAS—thyroid cancer	2.37e-05	9.78e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PTGS2—thyroid cancer	2.36e-05	9.72e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PTGS2—thyroid cancer	2.36e-05	9.72e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PTGS2—thyroid cancer	2.36e-05	9.72e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CCND1—thyroid cancer	2.35e-05	9.69e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CCND1—thyroid cancer	2.34e-05	9.65e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—NRAS—thyroid cancer	2.34e-05	9.65e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CCND1—thyroid cancer	2.33e-05	9.6e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PTGS2—thyroid cancer	2.32e-05	9.59e-05	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—HRAS—thyroid cancer	2.29e-05	9.45e-05	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—HRAS—thyroid cancer	2.28e-05	9.4e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—TPR—thyroid cancer	2.27e-05	9.38e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.27e-05	9.37e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—PTEN—thyroid cancer	2.27e-05	9.36e-05	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—HRAS—thyroid cancer	2.27e-05	9.36e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—PTEN—thyroid cancer	2.26e-05	9.31e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—PTEN—thyroid cancer	2.25e-05	9.27e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PRKAR1A—thyroid cancer	2.24e-05	9.23e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—NRAS—thyroid cancer	2.19e-05	9.03e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—NRAS—thyroid cancer	2.19e-05	9.03e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—NRAS—thyroid cancer	2.19e-05	9.03e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—NRAS—thyroid cancer	2.16e-05	8.91e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—HRAS—thyroid cancer	2.11e-05	8.72e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—HRAS—thyroid cancer	2.1e-05	8.68e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—HRAS—thyroid cancer	2.09e-05	8.64e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—TPR—thyroid cancer	2.09e-05	8.63e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—SLC5A5—thyroid cancer	2.08e-05	8.58e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—TPR—thyroid cancer	2.07e-05	8.55e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	2.06e-05	8.49e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PTEN—thyroid cancer	2.06e-05	8.48e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PTEN—thyroid cancer	2.06e-05	8.48e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PTEN—thyroid cancer	2.06e-05	8.48e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—KRAS—thyroid cancer	2.04e-05	8.42e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—KRAS—thyroid cancer	2.04e-05	8.42e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—KRAS—thyroid cancer	2.04e-05	8.42e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	2.04e-05	8.42e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.03e-05	8.37e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PTEN—thyroid cancer	2.03e-05	8.36e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—NRAS—thyroid cancer	2.02e-05	8.35e-05	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—AKT1—thyroid cancer	2.02e-05	8.34e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—NRAS—thyroid cancer	2.01e-05	8.31e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—KRAS—thyroid cancer	2.01e-05	8.3e-05	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—AKT1—thyroid cancer	2.01e-05	8.3e-05	CbGpPWpGaD
Bortezomib—PSMA1—Gene Expression—AKT1—thyroid cancer	2.01e-05	8.29e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—NRAS—thyroid cancer	2e-05	8.27e-05	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—AKT1—thyroid cancer	2e-05	8.26e-05	CbGpPWpGaD
Bortezomib—PSMD1—Gene Expression—AKT1—thyroid cancer	2e-05	8.25e-05	CbGpPWpGaD
Bortezomib—PSMD2—Gene Expression—AKT1—thyroid cancer	1.99e-05	8.21e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.95e-05	8.04e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—SLC5A5—thyroid cancer	1.91e-05	7.87e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—KRAS—thyroid cancer	1.88e-05	7.78e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—KRAS—thyroid cancer	1.88e-05	7.78e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—KRAS—thyroid cancer	1.88e-05	7.78e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—AKT1—thyroid cancer	1.87e-05	7.7e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—KRAS—thyroid cancer	1.86e-05	7.67e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—AKT1—thyroid cancer	1.86e-05	7.66e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.85e-05	7.63e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—AKT1—thyroid cancer	1.85e-05	7.63e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.79e-05	7.37e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CCND1—thyroid cancer	1.78e-05	7.35e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCND1—thyroid cancer	1.78e-05	7.35e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCND1—thyroid cancer	1.78e-05	7.35e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—TPR—thyroid cancer	1.77e-05	7.31e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCND1—thyroid cancer	1.76e-05	7.24e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—RXRA—thyroid cancer	1.75e-05	7.21e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	1.74e-05	7.19e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—KRAS—thyroid cancer	1.74e-05	7.18e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—HRAS—thyroid cancer	1.74e-05	7.16e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HRAS—thyroid cancer	1.74e-05	7.16e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—HRAS—thyroid cancer	1.74e-05	7.16e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—KRAS—thyroid cancer	1.73e-05	7.15e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—KRAS—thyroid cancer	1.73e-05	7.12e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PTEN—thyroid cancer	1.72e-05	7.09e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PTEN—thyroid cancer	1.72e-05	7.09e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PTEN—thyroid cancer	1.72e-05	7.09e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—HRAS—thyroid cancer	1.71e-05	7.06e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—SLC5A5—thyroid cancer	1.7e-05	7.02e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.7e-05	7.01e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PTEN—thyroid cancer	1.69e-05	6.99e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—RXRA—thyroid cancer	1.6e-05	6.61e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—HRAS—thyroid cancer	1.6e-05	6.61e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—HRAS—thyroid cancer	1.6e-05	6.61e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—HRAS—thyroid cancer	1.6e-05	6.61e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.6e-05	6.58e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.58e-05	6.52e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—HRAS—thyroid cancer	1.58e-05	6.52e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PPARG—thyroid cancer	1.57e-05	6.46e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—SLC5A5—thyroid cancer	1.57e-05	6.46e-05	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—AKT1—thyroid cancer	1.56e-05	6.45e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.56e-05	6.43e-05	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—AKT1—thyroid cancer	1.56e-05	6.42e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—SLC5A5—thyroid cancer	1.55e-05	6.4e-05	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—AKT1—thyroid cancer	1.55e-05	6.39e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—thyroid cancer	1.55e-05	6.39e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—thyroid cancer	1.54e-05	6.35e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NRAS—thyroid cancer	1.53e-05	6.33e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NRAS—thyroid cancer	1.53e-05	6.33e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NRAS—thyroid cancer	1.53e-05	6.33e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—thyroid cancer	1.53e-05	6.32e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—AKT1—thyroid cancer	1.53e-05	6.32e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—AKT1—thyroid cancer	1.53e-05	6.32e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—AKT1—thyroid cancer	1.53e-05	6.32e-05	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—AKT1—thyroid cancer	1.52e-05	6.28e-05	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—AKT1—thyroid cancer	1.52e-05	6.28e-05	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—AKT1—thyroid cancer	1.52e-05	6.28e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NRAS—thyroid cancer	1.51e-05	6.24e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—AKT1—thyroid cancer	1.51e-05	6.23e-05	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—AKT1—thyroid cancer	1.5e-05	6.2e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—HRAS—thyroid cancer	1.48e-05	6.11e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—HRAS—thyroid cancer	1.47e-05	6.08e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—HRAS—thyroid cancer	1.47e-05	6.05e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.45e-05	6e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—RXRA—thyroid cancer	1.43e-05	5.9e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—AKT1—thyroid cancer	1.41e-05	5.84e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—AKT1—thyroid cancer	1.41e-05	5.84e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—AKT1—thyroid cancer	1.41e-05	5.84e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—AKT1—thyroid cancer	1.39e-05	5.75e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.39e-05	5.74e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TPR—thyroid cancer	1.37e-05	5.64e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.35e-05	5.55e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SLC5A5—thyroid cancer	1.33e-05	5.47e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KRAS—thyroid cancer	1.32e-05	5.44e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KRAS—thyroid cancer	1.32e-05	5.44e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KRAS—thyroid cancer	1.32e-05	5.44e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—RXRA—thyroid cancer	1.32e-05	5.43e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AKT1—thyroid cancer	1.31e-05	5.39e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—RXRA—thyroid cancer	1.3e-05	5.38e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KRAS—thyroid cancer	1.3e-05	5.37e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AKT1—thyroid cancer	1.3e-05	5.37e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AKT1—thyroid cancer	1.29e-05	5.34e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.27e-05	5.23e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.24e-05	5.13e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—thyroid cancer	1.23e-05	5.08e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—AKT1—thyroid cancer	1.18e-05	4.89e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—AKT1—thyroid cancer	1.18e-05	4.89e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—AKT1—thyroid cancer	1.18e-05	4.89e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—thyroid cancer	1.17e-05	4.84e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—thyroid cancer	1.17e-05	4.84e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—thyroid cancer	1.17e-05	4.84e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—AKT1—thyroid cancer	1.17e-05	4.82e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—thyroid cancer	1.16e-05	4.77e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HRAS—thyroid cancer	1.12e-05	4.63e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HRAS—thyroid cancer	1.12e-05	4.63e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HRAS—thyroid cancer	1.12e-05	4.63e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—RXRA—thyroid cancer	1.11e-05	4.6e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HRAS—thyroid cancer	1.11e-05	4.56e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PPARG—thyroid cancer	1.1e-05	4.55e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.08e-05	4.47e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTEN—thyroid cancer	1.07e-05	4.43e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.02e-05	4.22e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PPARG—thyroid cancer	1.01e-05	4.17e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AKT1—thyroid cancer	9.91e-06	4.09e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AKT1—thyroid cancer	9.91e-06	4.09e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AKT1—thyroid cancer	9.91e-06	4.09e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AKT1—thyroid cancer	9.77e-06	4.03e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PPARG—thyroid cancer	9.03e-06	3.73e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—thyroid cancer	8.68e-06	3.58e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—RXRA—thyroid cancer	8.6e-06	3.55e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PPARG—thyroid cancer	8.31e-06	3.43e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PPARG—thyroid cancer	8.24e-06	3.4e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—thyroid cancer	7.96e-06	3.28e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTEN—thyroid cancer	7.57e-06	3.12e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—thyroid cancer	7.11e-06	2.93e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PPARG—thyroid cancer	7.04e-06	2.9e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTEN—thyroid cancer	6.94e-06	2.86e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—thyroid cancer	6.53e-06	2.7e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—thyroid cancer	6.48e-06	2.67e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTEN—thyroid cancer	6.2e-06	2.56e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—AKT1—thyroid cancer	6.19e-06	2.55e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTEN—thyroid cancer	5.7e-06	2.35e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTEN—thyroid cancer	5.65e-06	2.33e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—thyroid cancer	5.54e-06	2.28e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PPARG—thyroid cancer	5.43e-06	2.24e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTEN—thyroid cancer	4.83e-06	1.99e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AKT1—thyroid cancer	4.36e-06	1.8e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—thyroid cancer	4.27e-06	1.76e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AKT1—thyroid cancer	4e-06	1.65e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTEN—thyroid cancer	3.73e-06	1.54e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AKT1—thyroid cancer	3.57e-06	1.47e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AKT1—thyroid cancer	3.28e-06	1.35e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AKT1—thyroid cancer	3.26e-06	1.34e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AKT1—thyroid cancer	2.78e-06	1.15e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKT1—thyroid cancer	2.15e-06	8.86e-06	CbGpPWpGaD
